A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Author:

Thomas Kim S1,Batchelor Jonathan M1,Bath-Hextall Fiona2,Chalmers Joanne R1,Clarke Tessa1,Crowe Sally3,Delamere Finola M1,Eleftheriadou Viktoria1,Evans Nicholas4,Firkins Lester5,Greenlaw Nicola6,Lansbury Louise1,Lawton Sandra7,Layfield Carron1,Leonardi-Bee Jo8,Mason James9,Mitchell Eleanor10,Nankervis Helen1,Norrie John11,Nunn Andrew12,Ormerod Anthony D13,Patel Ramesh14,Perkins William7,Ravenscroft Jane C7,Schmitt Jochen15,Simpson Eric16,Whitton Maxine E1,Williams Hywel C1

Affiliation:

1. Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

2. School of Nursing, University of Nottingham, Nottingham, UK

3. Crowe Associates Ltd, Oxon, UK

4. Trust Headquarters, West Hertfordshire Hospital NHS Trust, Hemel Hempstead, UK

5. Strategy and Development Group, James Lind Alliance, Oxford, UK

6. Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

7. Dermatology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK

8. Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK

9. School of Medicine, Pharmacy and Health, Durham University, Durham, UK

10. Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK

11. Health Services Research Unit, University of Aberdeen, Aberdeen, UK

12. Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK

13. Division of Applied Medicine, University of Aberdeen, Aberdeen, UK

14. Radcliffe-on-Trent Health Centre, Nottingham, UK

15. Centre for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, Dresden, Germany

16. Oregon Health and Science University, Portland, OR, USA

Abstract

BackgroundSkin diseases are very common and can have a large impact on the quality of life of patients and caregivers. This programme addressed four diseases: (1) eczema, (2) vitiligo, (3) squamous cell skin cancer (SCC) and (4) pyoderma gangrenosum (PG).ObjectiveTo set priorities and reduce uncertainties for the treatment and prevention of skin disease in our four chosen diseases.DesignMixed methods including eight systematic reviews, three prioritisation exercises, two pilot randomised controlled trials (RCTs), three feasibility studies, two core outcome initiatives, four funding proposals for national RCTs and one completed national RCT.SettingSecondary care, primary care and the general population.ParticipantsPatients (and their caregivers) with eczema, vitiligo, SCC and PG, plus health-care professionals with an interest in skin disease.InterventionsOur three intervention studies included (1) barrier enhancement using emollients from birth to prevent eczema (pilot RCT); (2) handheld narrowband ultraviolet light B therapy for treating vitiligo (pilot RCT); and (3) oral ciclosporin (Neoral®, Novartis Pharmaceuticals) compared with oral prednisolone for managing PG (pragmatic national RCT).ResultsSystematic reviews included two overarching systematic reviews of RCTs of treatments for eczema and vitiligo, an umbrella review of systematic reviews of interventions for the prevention of eczema, two reviews of treatments for SCC (one included RCTs and the second included observational studies), and three reviews of outcome measures and outcome reporting. Three prioritisation partnership exercises identified 26 priority areas for future research in eczema, vitiligo and SCC. Two international consensus initiatives identified four core domains for future eczema trials and seven core domains for vitiligo trials. Two pilot RCTs and three feasibility studies critically informed development of four trial proposals for external funding, three of which are now funded and one is pending consideration by funders. Our pragmatic RCT tested the two commonly used systemic treatments for PG (prednisolone vs. ciclosporin) and found no difference in their clinical effectiveness or cost-effectiveness. Both drugs showed limited benefit. Only half of the participants’ ulcers had healed by 6 months. For those with healed ulcers, recurrence was common (30%). Different side effect profiles were noted for each drug, which can inform clinical decisions on an individual patient basis. Three researchers were trained to PhD level and a dermatology patient panel was established to ensure patient involvement in all aspects of the programme.ConclusionsFindings from this programme of work have already informed clinical guidelines and patient information resources. Feasibility studies have ensured that large national pragmatic trials will now be conducted on important areas of treatment uncertainty that address the needs of patients and the NHS. There is scope for considerable improvement in terms of trial design, conduct and reporting for RCTs of skin disease, which can be improved through wider collaboration, registration of trial protocols and complete reporting and international consensus over core outcome sets. Three national trials have now been funded as a result of this work. Two international initiatives to establish how best to measure the core outcome domains for eczema and vitiligo are ongoing.Trial registrationCurrent Controlled Trials Barrier Enhancement for Eczema Prevention (BEEP) (ISRCTN84854178 and NCT01142999), Study of Treatments fOr Pyoderma GAngrenosum Patients (STOP GAP) (ISRCTN35898459) and Hand Held NB-UVB for Early or Focal Vitiligo at Home (HI-Light Pilot Trial) (NCT01478945).FundingThis project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full inProgramme Grants for Applied Research; Vol. 4, No. 18. See the NIHR Journals Library website for further project information.

Funder

National Institute for Health Research

Publisher

National Institute for Health Research

Subject

Automotive Engineering

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3